CTNM Contineum Therapeutics, Inc.

NASDAQ
$9.24

Contineum Therapeutics, Inc. (CTNM) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.49 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.6% since its last earnings release on November 3, 2026.

Contineum Therapeutics Missed Consensus Estimates
Tuesday, November 3, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.49)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Contineum Therapeutics, Inc.

Contineum Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies which target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need. The company's product pipeline includes PIPE-791 and PIPE-307. Contineum Therapeutics Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.